Bruton's tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment.
Agammaglobulinaemia Tyrosine Kinase
/ antagonists & inhibitors
Animals
B-Lymphocytes
/ immunology
Humans
Molecular Targeted Therapy
/ methods
Myeloid Cells
/ drug effects
Myeloid-Derived Suppressor Cells
/ immunology
Protein Kinase Inhibitors
/ pharmacology
Receptors, Antigen, B-Cell
/ metabolism
Tumor Microenvironment
/ drug effects
Tumor-Associated Macrophages
/ drug effects
BTK
Bruton’s tyrosine kinase
Myeloid-derived suppressor cells
Tumor-associated macrophage
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
12
10
2020
accepted:
02
03
2021
pubmed:
6
4
2021
medline:
24
8
2021
entrez:
5
4
2021
Statut:
ppublish
Résumé
Bruton's tyrosine kinase (BTK) is a non-receptor kinase belonging to the Tec family of kinases. The role of BTK in B cell receptor signaling is well defined and is known to play a key role in the proliferation and survival of malignant B cells. Moreover, BTK has been found to be expressed in cells of the myeloid lineage. BTK has been shown to contribute to a variety of cellular pathways in myeloid cells including signaling in the NLRP3 inflammasome, receptor activation of nuclear factor-κβ and inflammation, chemokine receptor activation affecting migration, and phagocytosis. Myeloid cells are crucial components of the tumor microenvironment and suppressive myeloid cells contribute to cancer progression, highlighting a potential role for BTK inhibition in the treatment of malignancy. The increased interest in BTK inhibition in cancer has resulted in many preclinical studies that are testing the efficacy of using single-agent BTK inhibitors. Moreover, the ability of tumor cells to develop resistance to single-agent checkpoint inhibitors has resulted in clinical studies utilizing BTK inhibitors in combination with these agents to improve clinical responses. Furthermore, BTK regulates the immune response in microbial and viral infections through B cells and myeloid cells such as monocytes and macrophages. In this review, we describe the role that BTK plays in supporting suppressive myeloid cells, including myeloid-derived suppressor cells (MDSC) and tumor-associated macrophages (TAM), while also discussing the anticancer effects of BTK inhibition and briefly describe the role of BTK signaling and BTK inhibition in microbial and viral infections.
Identifiants
pubmed: 33818636
doi: 10.1007/s00262-021-02908-5
pii: 10.1007/s00262-021-02908-5
pmc: PMC8019691
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Receptors, Antigen, B-Cell
0
Agammaglobulinaemia Tyrosine Kinase
EC 2.7.10.2
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2439-2451Subventions
Organisme : NIH HHS
ID : P01CA95426
Pays : United States
Organisme : NIH HHS
ID : T32CA90338-27
Pays : United States
Organisme : NIH HHS
ID : P01CA95426
Pays : United States
Organisme : NIH HHS
ID : T32CA90338-27
Pays : United States
Informations de copyright
© 2021. The Author(s).
Références
Mol Immunol. 2004 Jul;41(6-7):599-613
pubmed: 15219998
Blood Cancer J. 2018 Nov 5;8(11):100
pubmed: 30397191
J Natl Cancer Inst. 2014 Sep 10;106(9):
pubmed: 25214559
J Biomed Sci. 2019 Oct 20;26(1):78
pubmed: 31629410
Nature. 2012 Sep 13;489(7415):309-12
pubmed: 22885698
Science. 1993 Jul 16;261(5119):355-8
pubmed: 8332900
EMBO Mol Med. 2015 Jan 30;7(3):240-58
pubmed: 25637383
Blood. 2012 Dec 6;120(24):4684-91
pubmed: 22875912
Immunity. 1998 Apr;8(4):509-16
pubmed: 9586640
Blood. 2018 Nov 1;132(18):1985-1988
pubmed: 30021784
Nat Med. 2011 Nov 07;17(11):1391-401
pubmed: 22064429
J Immunol. 2008 Jul 1;181(1):288-98
pubmed: 18566394
J Immunother Cancer. 2020 Feb;8(1):
pubmed: 32114502
Ann Rheum Dis. 2015 Aug;74(8):1603-11
pubmed: 24764451
Eur J Immunol. 2007 Apr;37(4):1033-42
pubmed: 17372989
Invest New Drugs. 2014 Dec;32(6):1096-104
pubmed: 25081321
Oncoimmunology. 2019 Sep 5;8(11):1659704
pubmed: 31646085
mBio. 2013 Jul 02;4(4):
pubmed: 23820392
Front Immunol. 2018 Jan 22;8:1986
pubmed: 29403475
J Clin Oncol. 2013 Jan 1;31(1):88-94
pubmed: 23045577
Clin Cancer Res. 2018 Apr 15;24(8):1891-1904
pubmed: 29363526
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Clin Cancer Res. 2014 Mar 15;20(6):1601-9
pubmed: 24323899
Br J Cancer. 2020 Mar;122(7):1005-1013
pubmed: 32025027
Nature. 1997 Sep 18;389(6648):296-9
pubmed: 9305846
Lancet. 2018 Feb 17;391(10121):659-667
pubmed: 29241979
J Immunol. 2006 Mar 15;176(6):3635-41
pubmed: 16517732
Arthritis Res Ther. 2011 Jul 13;13(4):R115
pubmed: 21752263
J Allergy Clin Immunol. 2017 Oct;140(4):1054-1067.e10
pubmed: 28216434
Proc Natl Acad Sci U S A. 2006 Jan 3;103(1):153-8
pubmed: 16371463
FEBS J. 2011 Jun;278(12):2001-10
pubmed: 21518255
Clin Immunol. 2016 Mar;164:65-77
pubmed: 26821304
J Biol Chem. 2007 Dec 21;282(51):36953-60
pubmed: 17932028
Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80
pubmed: 20615965
PLoS One. 2015 May 20;10(5):e0127028
pubmed: 25992611
Nat Rev Immunol. 2008 Jan;8(1):34-47
pubmed: 18064051
Curr Hematol Malig Rep. 2014 Mar;9(1):44-9
pubmed: 24357428
Blood. 2020 May 21;135(21):1912-1915
pubmed: 32302379
Nat Med. 2011 Jul 07;17(7):796-808
pubmed: 21738161
Microbiol Spectr. 2016 Dec;4(6):
pubmed: 28087938
PLoS One. 2013;8(3):e60476
pubmed: 23544144
J Immunol. 2010 Aug 15;185(4):2273-84
pubmed: 20644162
Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8601-5
pubmed: 7567982
Nat Rev Immunol. 2009 Mar;9(3):162-74
pubmed: 19197294
Cancer Discov. 2016 Mar;6(3):270-85
pubmed: 26715645
J Exp Med. 2011 Sep 26;208(10):2005-16
pubmed: 21930765
Ther Adv Hematol. 2014 Aug;5(4):121-33
pubmed: 25360238
Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11256-60
pubmed: 7972043
Cell. 1993 Jan 29;72(2):279-90
pubmed: 8425221
Adv Immunol. 2014;122:129-75
pubmed: 24507157
Blood. 2004 Aug 15;104(4):1191-7
pubmed: 15117762
Blood. 2007 Mar 15;109(6):2553-6
pubmed: 17090647
Aging Cell. 2017 Jun;16(3):480-487
pubmed: 28229533
Cancer Res. 2016 Apr 15;76(8):2125-36
pubmed: 26880800
N Engl J Med. 2014 Jul 17;371(3):213-23
pubmed: 24881631
Histol Histopathol. 2005 Jul;20(3):945-55
pubmed: 15944945
Eur J Haematol. 2015 Mar;94(3):193-205
pubmed: 25080849
PLoS Pathog. 2013;9(6):e1003446
pubmed: 23825946
Nat Rev Mol Cell Biol. 2009 Dec;10(12):819-30
pubmed: 19935667
Nat Immunol. 2011 May;12(5):416-24
pubmed: 21441935
Blood. 2012 Mar 15;119(11):2590-4
pubmed: 22279054
J Neuroimmune Pharmacol. 2019 Sep;14(3):448-461
pubmed: 30758770
Blood. 2014 May 22;123(21):3286-95
pubmed: 24659631
EMBO J. 1994 Mar 15;13(6):1341-9
pubmed: 8137818
PLoS Pathog. 2014 Dec 04;10(12):e1004525
pubmed: 25474208
Mol Cancer. 2018 Feb 19;17(1):57
pubmed: 29455639
PLoS One. 2014 May 02;9(5):e96565
pubmed: 24794217
Proc Natl Acad Sci U S A. 2012 Apr 10;109(15):5791-6
pubmed: 22454496
Cancer Treat Rev. 2017 Jul;58:41-50
pubmed: 28641100
Acta Biomater. 2019 Jul 1;92:184-195
pubmed: 31108259
Immunity. 2007 Jan;26(1):93-104
pubmed: 17239630
N Engl J Med. 2016 Jan 28;374(4):323-32
pubmed: 26641137
Mol Cell Biol. 1994 Aug;14(8):5108-13
pubmed: 7518558
J Inflamm (Lond). 2006 May 04;3:8
pubmed: 16674821
Eur J Immunol. 1994 Dec;24(12):3100-5
pubmed: 7805739
J Immunol. 1999 Jul 15;163(2):875-83
pubmed: 10395682
J Biol Chem. 2006 Apr 14;281(15):10489-95
pubmed: 16439361
J Biol Chem. 2003 Jul 11;278(28):26258-64
pubmed: 12724322
Blood. 2003 Sep 15;102(6):2138-45
pubmed: 12750171
Cancer Res. 2015 Apr 15;75(8):1675-81
pubmed: 25878147
J Exp Med. 2003 Nov 17;198(10):1539-50
pubmed: 14610042
Nat Commun. 2015 Jun 10;6:7360
pubmed: 26059659
Blood Adv. 2017 Dec 12;1(26):2610-2623
pubmed: 29296914
Cell. 2008 Mar 7;132(5):794-806
pubmed: 18329366
Nature. 2012 Nov 29;491(7426):779-83
pubmed: 23086146
J Immunol. 2014 Sep 1;193(5):2574-86
pubmed: 25063873
J Immunol. 1994 Jan 15;152(2):557-65
pubmed: 8283037
Science. 1993 Jul 16;261(5119):358-61
pubmed: 8332901
Am J Hematol. 2020 Jul;95(7):E174-E178
pubmed: 32267009
J Biol Chem. 2001 Jan 19;276(3):1715-9
pubmed: 11042193
Am J Physiol Lung Cell Mol Physiol. 2018 Jul 1;315(1):L52-L58
pubmed: 29516781
Cell Biochem Biophys. 2014 Nov;70(2):1265-75
pubmed: 24906236
J Biol Chem. 2002 Jan 11;277(2):1488-92
pubmed: 11698416
Neoplasia. 2011 Nov;13(11):1093-100
pubmed: 22131884
J Exp Med. 2000 May 15;191(10):1745-54
pubmed: 10811867
J Hematol Oncol. 2013 Aug 19;6:59
pubmed: 23958373
J Cell Mol Med. 2019 Oct;23(10):6522-6529
pubmed: 31397086
Oncotarget. 2017 Jun 13;8(24):39218-39229
pubmed: 28424405
J Biol Chem. 2000 Apr 7;275(14):10175-81
pubmed: 10744701
Lipids Health Dis. 2017 Nov 18;16(1):217
pubmed: 29151018
J Exp Med. 2003 Jun 16;197(12):1603-11
pubmed: 12810683
Curr Opin Pharmacol. 2017 Aug;35:12-19
pubmed: 28538141
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
N Engl J Med. 2014 Jan 23;370(4):341-51
pubmed: 24450892
Nature. 1993 Jan 21;361(6409):226-33
pubmed: 8380905
Nat Rev Cancer. 2014 Apr;14(4):219-32
pubmed: 24658273
Mol Med. 2019 Jan 15;25(1):3
pubmed: 30646846
J Exp Med. 2000 May 15;191(10):1735-44
pubmed: 10811866
Blood. 2012 Aug 30;120(9):1877-87
pubmed: 22689860
Clin Cancer Res. 2020 Jul 15;26(14):3514-3516
pubmed: 32345646
Cell Mol Immunol. 2020 Oct;17(10):1042-1052
pubmed: 31431692
Sci Immunol. 2020 Jun 5;5(48):
pubmed: 32503877
Cancer Immunol Immunother. 2014 Mar;63(3):247-57
pubmed: 24357148
J Biol Chem. 2012 Jul 6;287(28):23769-78
pubmed: 22589540
J Clin Invest. 2020 Apr 1;130(4):1793-1807
pubmed: 31895698
J Immunol. 2002 Mar 15;168(6):2914-21
pubmed: 11884462
J Hematol Oncol. 2017 Feb 28;10(1):58
pubmed: 28241846
Clin Immunol. 2010 Oct;137(1):74-80
pubmed: 20634142
Bone. 2014 Mar;60:8-15
pubmed: 24316417
Curr Oncol. 2019 Apr;26(2):e233-e240
pubmed: 31043832
Breast Cancer Res. 2015 Aug 05;17:101
pubmed: 26243145